Media Centre
© Enthera. All rights reserved
Enthera Srl
Corporate Headquarters: Via Borgogna, 5, 20122 Milan Italy
Registered office: Via Visconti di Modrone Uberto, 18, 20122 Milan Italy
Phone: +39 02 49533580
Email: info@entherapharmaceuticals.com
Enthera Srl
Corporate Headquarters: Via Borgogna, 5, 20122 Milan Italy
Registered office: Via Visconti di Modrone Uberto, 18, 20122 Milan Italy
Phone: +39 02 49533580
Email: info@entherapharmaceuticals.com
This website uses only technical cookies and does not perform any profiling or collection of personal data through cookies. Simply browsing the website does not require the user’s consent.
Website by Instinctif Partners
Enthera Pharmaceuticals appoints Kazumi Shiosaki to its Board of Directors and Lisa Olson to its Scientific Advisory Board to push forward company growth and development
/in Press ReleasesMilan, Italy, 3 December 2020 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, announces that it has appointed Kazumi Shiosaki to its Board of Directors, and Lisa Olson to its Scientific Advisory Board.
Enthera Pharmaceuticals raises €28 million in Series A financing to advance restorative therapy for type 1 diabetes and inflammatory bowel disease
/in Press ReleasesMilan, Italy – Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, today announces the completion of a €28 million Series A financing round.
Enthera, the first spin-off of BiovelocITA, completed €4 million seed-expansion financing
/in Press ReleasesEnthera, an innovative Italian start-up dedicated to the research and development of innovative therapeutics to treat Type 1 Diabetes and gastrointestinal diseases, received an investment of €4 million led by Sofinnova along with the JDRF T1D Fund (the venture capital fund of the authoritative US JDRF Foundation dedicated to promoting research on Type 1 Diabetes), the accelerator BiovelocITA and its shareholders.